![Christopher Zosh](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Christopher Zosh
Directeur Financier/CFO chez
STATERA BIOPHARMA, INC.
Profil
Christopher Zosh currently works at Panacela Labs, Inc., as Director from 2017 and Statera Biopharma, Inc., as EVP-Finance, Chief Financial & Accounting Officer from 2022.
Mr. Zosh also formerly worked at Cleveland BioLabs, Inc., as CAO, Chief Executive & Financial Officer from 2019 to 2021.
Mr. Zosh received his undergraduate degree from State University of New York at Buffalo.
Postes actifs de Christopher Zosh
| Sociétés | Poste | Début |
|---|---|---|
| STATERA BIOPHARMA, INC. | Directeur Financier/CFO | 27/05/2022 |
Panacela Labs, Inc.
 Panacela Labs, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs against cancer | Directeur/Membre du Conseil | 01/07/2017 |
Anciens postes connus de Christopher Zosh
| Sociétés | Poste | Fin |
|---|---|---|
| STATERA BIOPHARMA, INC. | Directeur Général | 27/07/2021 |
Formation de Christopher Zosh
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
6
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Cleveland BioLabs, Inc.
 Cleveland BioLabs, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel therapeutics to activate the immune system and address serious medical needs | Health Technology |
Panacela Labs, Inc.
Panacela Labs, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs against cancer | Health Technology |
State University of New York at Buffalo
 State University of New York at Buffalo Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Statera Biopharma, Inc.
 Statera Biopharma, Inc. BiotechnologyHealth Technology Operates as clinical-stage biopharmaceutical company, which develops novel small molecule immunotherapies | Health Technology |
